JAKARTA - The COVID-19 pandemic is a momentum for Indonesia to continue to strengthen and transform the national health system towards an Indonesia that is independent and has good health resilience.
The government continues to encourage various strengthening efforts, including the acceleration of independence and the development of plasma fractionation which produces plasma derivative products in order to meet domestic needs and increase industrial competitiveness and industrial capacity in Indonesia.
Coordinating Minister for Economic Affairs Airlangga Hartarto said that plasma fractionation has a large market potential and global demand for plasma derivative products is 25 million liters per year. This was conveyed at the Seminar and Technical Working Meeting at the National Level of the Indonesian Red Cross Blood Donor Unit (UDD PMI) with the theme "Plasma Fractionation" in Jakarta, Tuesday 14 December.
"Based on experience in handling COVID-19, we see that the capability of the domestic pharmaceutical industry is important because apart from saving the country's foreign exchange, it also creates a fast response to domestic needs. Alhamdulillah, our health sector's ability is quite responsive, especially when coupled with blood fractionation capabilities. ," said Coordinating Minister Airlangga.
In terms of regulation, various regulations have been issued as evidence of the Government's seriousness in efforts to develop plasma fractionation, including Government Regulation (PP) Number 7 of 2011 concerning Blood Services and Regulation of the Minister of Health (Permenkes) Number 15 of 2019 which regulates the Implementation of Plasma Fractionation.
In PP No. 7 of 2011, the government makes regulations that allow legal entities that already have a production permit from the minister to become plasma fractionation organizers. Plasma fractionated products must meet quality standards of safety and efficacy to protect product users.
Furthermore, Permenkes No. 15 of 2019 requires plasma fractionation facilities to have a CPOB (Good Manufacturing Practice) certificate for plasma-derived drug products so that consumers can be assured that the plasma-derived products produced are of good quality.
"One of the targets of the COVID-19 Handling Committee and National Economic Recovery is to increase domestic production capabilities, especially vaccines, therapeutics, and including blood affairs. Regarding plasma fractionation, the regulations are already in place. private sector," said Coordinating Minister Airlangga.
Also present on the occasion were the Minister of Health, represented by Deputy Minister of Health Dante Saksosno Harbuwono, Chairman of PMI Jusuf Kalla and his staff, Director of Standardization of Drugs, Narcotics, Psychotropics, Precursors and Addictive Substances of the Food and Drug Supervisory Agency Lucia Rizka Andalusia, and Head of Division Business Planning and Strategy of PT Bio Farma (Persero) Taufik Wilmansyah.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
